CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 3 enrolled
Drug / intervention
suvorexant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02593682
NCT02593682Phase 4Completed
CompareCT.gov

The Role of Orexin in Human Panic Disorder

University of California, San Francisco·interventional·Posted Nov 2, 2015·Updated Jul 2, 2021

In Brief

A Phase 4 clinical trial evaluating suvorexant and placebo for Panic Disorder. Completed, enrolled 3 participants across 1 site.

Detailed Summary

The purpose of this study is to provide some information (pilot data) about whether the study drug, suvorexant, (1) affects levels of orexin in people with panic disorder, and (2) is associated with decreased panic symptoms in response to a carbon dioxide (CO2) challenge.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPanic Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2, 2015
Enrollment StartMay 1, 2016
Primary CompletionMar 13, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.7 years ago

Interventions

suvorexantdrug

placebodrug